Literature DB >> 28426122

Efficacy of androgen deprivation therapy and the role of oxidative stress.

D K Price1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28426122      PMCID： PMC5834065          DOI： 10.1093/annonc/mdx001

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

1.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

Review 2.  Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

Authors:  Masaki Shiota; Akira Yokomizo; Seiji Naito
Journal:  J Mol Endocrinol       Date:  2011-07-12       Impact factor: 5.098

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 4.  Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Naohiro Fujimoto; Seiji Naito
Journal:  Curr Cancer Drug Targets       Date:  2011-09       Impact factor: 3.428

5.  Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Authors:  Masaki Shiota; Ario Takeuchi; YooHyun Song; Akira Yokomizo; Eiji Kashiwagi; Takeshi Uchiumi; Kentaro Kuroiwa; Katsunori Tatsugami; Naohiro Fujimoto; Yoshinao Oda; Seiji Naito
Journal:  Endocr Relat Cancer       Date:  2011-07-11       Impact factor: 5.678

Review 6.  Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Seiji Naito
Journal:  Free Radic Biol Med       Date:  2011-07-23       Impact factor: 7.376

7.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

8.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

Review 9.  Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Seiji Naito
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

10.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
View more
  2 in total

Review 1.  Redox Control of the Dormant Cancer Cell Life Cycle.

Authors:  Bowen Li; Yichun Huang; Hui Ming; Edouard C Nice; Rongrong Xuan; Canhua Huang
Journal:  Cells       Date:  2021-10-09       Impact factor: 6.600

2.  Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.

Authors:  Iya Eze Bassey; Bukola Abosede Emodi; Uwem Okon Akpan; Idorenyin Francesca Akpan Iyakndue; Edim Azubuike Anakebe; Bassey Edward Icha; Henry Afamuefuna Efobi; Akan Joshua Ntinya; Alphonsus Ekpe Udoh
Journal:  JCO Glob Oncol       Date:  2020-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.